This study is a cross-sectional study aimed to assess the rate of occurrence of secondary occult hepatitis C virus (HCV) infection in patients treated with the combination of sofosbuvir and daclatasvir. This study included 40 patients whose serum turned negative for HCV ribonucleic acid (HCV RNA) via real time polymerase chain reaction (RT-PCR) after 3 months of the treatment. Blood samples on EDTA were collected from the patients to detect HCV RNA in peripheral blood mononuclear cells (PBMCs). At the end of the study there were 30 PBMCs HCV RNA negative patients and 10 PBMCs HCV RNA positive patients. | Secondary occult hepatitis C virus infection (HCV) in chronic HCV patients after treatment with sofosbuvir and daclatasvir
